Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Skin Neoplasms | 50 | 2020 | 214 | 8.260 |
Why?
|
Skin | 25 | 2018 | 211 | 3.610 |
Why?
|
Skin Diseases, Vascular | 7 | 2019 | 11 | 2.050 |
Why?
|
Immunohistochemistry | 28 | 2019 | 538 | 1.940 |
Why?
|
Exanthema | 4 | 2018 | 21 | 1.880 |
Why?
|
Humans | 133 | 2020 | 31974 | 1.470 |
Why?
|
Carcinoma, Squamous Cell | 8 | 2019 | 154 | 1.460 |
Why?
|
Telangiectasis | 3 | 2019 | 5 | 1.430 |
Why?
|
Skin Diseases | 10 | 2017 | 142 | 1.400 |
Why?
|
Collagen Type I | 2 | 2019 | 42 | 1.370 |
Why?
|
Diagnosis, Differential | 31 | 2019 | 517 | 1.350 |
Why?
|
Dermatology | 11 | 2017 | 163 | 1.200 |
Why?
|
Xanthomatosis | 2 | 2017 | 3 | 1.190 |
Why?
|
Biopsy, Needle | 11 | 2019 | 93 | 1.180 |
Why?
|
Middle Aged | 61 | 2020 | 11804 | 1.070 |
Why?
|
Pathology | 7 | 2013 | 17 | 1.040 |
Why?
|
Female | 74 | 2020 | 19939 | 1.020 |
Why?
|
Hemangioendothelioma | 5 | 2015 | 10 | 0.980 |
Why?
|
Mycosis Fungoides | 6 | 2017 | 12 | 0.970 |
Why?
|
Soft Tissue Neoplasms | 5 | 2018 | 39 | 0.950 |
Why?
|
Tattooing | 3 | 2017 | 7 | 0.930 |
Why?
|
Male | 61 | 2020 | 19143 | 0.920 |
Why?
|
Erythema | 6 | 2019 | 26 | 0.910 |
Why?
|
Pellagra | 2 | 2016 | 3 | 0.910 |
Why?
|
Melanoma | 10 | 2014 | 164 | 0.900 |
Why?
|
Lichen Sclerosus et Atrophicus | 2 | 2017 | 9 | 0.880 |
Why?
|
Nail Diseases | 2 | 2019 | 5 | 0.840 |
Why?
|
Adult | 42 | 2020 | 9339 | 0.830 |
Why?
|
Aged | 40 | 2020 | 10294 | 0.770 |
Why?
|
Biopsy | 13 | 2019 | 259 | 0.760 |
Why?
|
Carcinoma, Merkel Cell | 2 | 2019 | 9 | 0.760 |
Why?
|
Sweet Syndrome | 2 | 2019 | 6 | 0.730 |
Why?
|
Immunocompromised Host | 3 | 2019 | 51 | 0.730 |
Why?
|
Langerhans Cells | 1 | 2020 | 2 | 0.720 |
Why?
|
Keratosis | 2 | 2019 | 23 | 0.710 |
Why?
|
Cellulitis | 1 | 2019 | 10 | 0.680 |
Why?
|
Streptococcal Infections | 1 | 2019 | 22 | 0.680 |
Why?
|
Scalp | 3 | 2020 | 38 | 0.680 |
Why?
|
Deficiency Diseases | 2 | 2010 | 3 | 0.670 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2019 | 20 | 0.670 |
Why?
|
Zinc | 2 | 2010 | 32 | 0.650 |
Why?
|
Leukemic Infiltration | 1 | 2018 | 2 | 0.650 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 9 | 0.640 |
Why?
|
Ossification, Heterotopic | 2 | 2009 | 18 | 0.630 |
Why?
|
Pagetoid Reticulosis | 1 | 2018 | 1 | 0.620 |
Why?
|
Anti-Bacterial Agents | 2 | 2019 | 323 | 0.620 |
Why?
|
Coloring Agents | 2 | 2017 | 29 | 0.600 |
Why?
|
Fibroma | 3 | 2014 | 10 | 0.600 |
Why?
|
Mast Cells | 2 | 2017 | 11 | 0.600 |
Why?
|
Certification | 3 | 2009 | 27 | 0.600 |
Why?
|
Panniculitis, Lupus Erythematosus | 3 | 2014 | 6 | 0.600 |
Why?
|
Hemangioma | 4 | 2019 | 19 | 0.590 |
Why?
|
Urticaria Pigmentosa | 1 | 2017 | 1 | 0.590 |
Why?
|
Fingers | 3 | 2019 | 64 | 0.580 |
Why?
|
Pathology, Clinical | 3 | 2018 | 13 | 0.580 |
Why?
|
Hand Dermatoses | 2 | 2016 | 10 | 0.570 |
Why?
|
Thigh | 2 | 2019 | 42 | 0.530 |
Why?
|
Hemangiosarcoma | 4 | 2010 | 9 | 0.530 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2015 | 4 | 0.520 |
Why?
|
Treatment Outcome | 9 | 2019 | 3302 | 0.500 |
Why?
|
Dermatitis | 4 | 2017 | 21 | 0.480 |
Why?
|
Blood Vessels | 2 | 2009 | 48 | 0.470 |
Why?
|
Histiocytoma, Benign Fibrous | 4 | 2009 | 5 | 0.470 |
Why?
|
Aged, 80 and over | 15 | 2020 | 3988 | 0.460 |
Why?
|
Neoplasm Invasiveness | 5 | 2014 | 190 | 0.460 |
Why?
|
Neoplasms, Adnexal and Skin Appendage | 1 | 2013 | 2 | 0.460 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2013 | 4 | 0.450 |
Why?
|
Head and Neck Neoplasms | 2 | 2007 | 130 | 0.450 |
Why?
|
Parakeratosis | 2 | 2003 | 3 | 0.420 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2015 | 367 | 0.420 |
Why?
|
Axilla | 2 | 2003 | 18 | 0.420 |
Why?
|
Epidermis | 6 | 2020 | 30 | 0.410 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2002 | 44 | 0.410 |
Why?
|
Keratinocytes | 2 | 2010 | 29 | 0.400 |
Why?
|
Polycythemia Vera | 1 | 2010 | 2 | 0.380 |
Why?
|
Paracoccidioidomycosis | 2 | 2009 | 2 | 0.370 |
Why?
|
Niacin | 1 | 2010 | 7 | 0.370 |
Why?
|
Acantholysis | 1 | 2010 | 1 | 0.370 |
Why?
|
Ichthyosis | 1 | 2010 | 1 | 0.370 |
Why?
|
Giant Cells | 2 | 2009 | 4 | 0.350 |
Why?
|
Pemphigoid, Bullous | 2 | 2019 | 9 | 0.350 |
Why?
|
Epithelioid Cells | 1 | 2009 | 1 | 0.340 |
Why?
|
Perivascular Epithelioid Cell Neoplasms | 1 | 2009 | 1 | 0.340 |
Why?
|
Desmin | 1 | 2009 | 12 | 0.340 |
Why?
|
Knee | 2 | 2019 | 33 | 0.340 |
Why?
|
Elbow | 2 | 2019 | 26 | 0.340 |
Why?
|
Mycoses | 2 | 2009 | 20 | 0.340 |
Why?
|
Osteoclasts | 1 | 2009 | 22 | 0.340 |
Why?
|
Paracoccidioides | 1 | 2009 | 1 | 0.330 |
Why?
|
Bottle-Nosed Dolphin | 1 | 2009 | 1 | 0.330 |
Why?
|
Fever | 2 | 2019 | 61 | 0.330 |
Why?
|
Child | 8 | 2017 | 2436 | 0.330 |
Why?
|
Dermatomyositis | 1 | 2009 | 19 | 0.330 |
Why?
|
Neoplasms, Vascular Tissue | 3 | 2013 | 7 | 0.320 |
Why?
|
Lymphoma, B-Cell | 2 | 2002 | 11 | 0.310 |
Why?
|
Endothelium, Lymphatic | 1 | 2008 | 1 | 0.310 |
Why?
|
Vascular Endothelial Growth Factor Receptor-3 | 1 | 2008 | 1 | 0.310 |
Why?
|
Sialoglycoproteins | 1 | 2008 | 8 | 0.310 |
Why?
|
Keratoacanthoma | 1 | 2008 | 1 | 0.310 |
Why?
|
Mouth Mucosa | 1 | 2008 | 30 | 0.310 |
Why?
|
Transglutaminases | 1 | 2007 | 1 | 0.300 |
Why?
|
Epidermal Cyst | 1 | 2007 | 4 | 0.300 |
Why?
|
Acrodermatitis | 1 | 2007 | 1 | 0.300 |
Why?
|
Arm | 2 | 2017 | 35 | 0.290 |
Why?
|
Follow-Up Studies | 4 | 2019 | 2265 | 0.290 |
Why?
|
Renal Insufficiency | 1 | 2007 | 58 | 0.290 |
Why?
|
Severity of Illness Index | 3 | 2019 | 881 | 0.290 |
Why?
|
Carcinoma | 3 | 2013 | 91 | 0.280 |
Why?
|
Upper Extremity | 3 | 2017 | 57 | 0.270 |
Why?
|
Hypopigmentation | 3 | 2017 | 7 | 0.270 |
Why?
|
Hamartoma | 2 | 1997 | 10 | 0.270 |
Why?
|
Neurilemmoma | 2 | 2005 | 16 | 0.270 |
Why?
|
Opportunistic Infections | 2 | 2002 | 17 | 0.270 |
Why?
|
Lower Extremity | 2 | 2017 | 100 | 0.270 |
Why?
|
Granuloma | 2 | 2002 | 14 | 0.260 |
Why?
|
Specialty Boards | 1 | 2005 | 9 | 0.260 |
Why?
|
Tongue Neoplasms | 2 | 2003 | 5 | 0.260 |
Why?
|
Eyelid Neoplasms | 2 | 2018 | 2 | 0.260 |
Why?
|
Carcinoma, Basal Cell | 3 | 2014 | 26 | 0.250 |
Why?
|
Drug Therapy, Combination | 3 | 2019 | 288 | 0.250 |
Why?
|
Risk Assessment | 4 | 2019 | 1422 | 0.250 |
Why?
|
Adolescent | 11 | 2013 | 3537 | 0.250 |
Why?
|
Dermatomycoses | 2 | 2002 | 7 | 0.240 |
Why?
|
Education, Medical, Graduate | 3 | 2012 | 128 | 0.240 |
Why?
|
Eye Neoplasms | 1 | 2004 | 3 | 0.240 |
Why?
|
Mass Screening | 1 | 2007 | 263 | 0.240 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2004 | 18 | 0.240 |
Why?
|
Facial Neoplasms | 2 | 2001 | 9 | 0.230 |
Why?
|
Lupus Erythematosus, Discoid | 2 | 2004 | 7 | 0.230 |
Why?
|
Breast Neoplasms | 3 | 2020 | 765 | 0.230 |
Why?
|
Remission, Spontaneous | 4 | 2015 | 14 | 0.230 |
Why?
|
Ganglioneuroma | 1 | 2003 | 2 | 0.220 |
Why?
|
Sarcoma, Alveolar Soft Part | 1 | 2003 | 1 | 0.220 |
Why?
|
Multiple Myeloma | 1 | 2003 | 20 | 0.220 |
Why?
|
Flow Cytometry | 3 | 2005 | 185 | 0.220 |
Why?
|
Fusarium | 1 | 2002 | 2 | 0.220 |
Why?
|
Fibrosarcoma | 1 | 2002 | 4 | 0.220 |
Why?
|
Keratosis, Actinic | 2 | 2015 | 20 | 0.220 |
Why?
|
Lymph Nodes | 2 | 2019 | 107 | 0.210 |
Why?
|
Prognosis | 6 | 2015 | 1495 | 0.210 |
Why?
|
Eosinophils | 2 | 2014 | 29 | 0.210 |
Why?
|
Rare Diseases | 2 | 2019 | 21 | 0.210 |
Why?
|
Tetrahydronaphthalenes | 1 | 2002 | 6 | 0.210 |
Why?
|
Antigens, CD | 3 | 2009 | 103 | 0.210 |
Why?
|
DNA, Neoplasm | 2 | 1993 | 55 | 0.210 |
Why?
|
Gingival Neoplasms | 1 | 2002 | 1 | 0.210 |
Why?
|
Periodontitis | 1 | 2002 | 9 | 0.210 |
Why?
|
Arthritis, Rheumatoid | 1 | 2002 | 40 | 0.210 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2002 | 15 | 0.200 |
Why?
|
Dermoscopy | 2 | 2020 | 12 | 0.200 |
Why?
|
Neoplasm Proteins | 6 | 2009 | 148 | 0.200 |
Why?
|
Precancerous Conditions | 2 | 2013 | 27 | 0.200 |
Why?
|
Carcinoma, Skin Appendage | 1 | 2001 | 1 | 0.200 |
Why?
|
Darier Disease | 1 | 2001 | 2 | 0.190 |
Why?
|
Antigens, Neoplasm | 4 | 2009 | 45 | 0.190 |
Why?
|
Toes | 2 | 2017 | 15 | 0.190 |
Why?
|
Image Processing, Computer-Assisted | 2 | 1993 | 226 | 0.190 |
Why?
|
Hyperpigmentation | 2 | 2013 | 17 | 0.190 |
Why?
|
Endothelium, Vascular | 4 | 2009 | 156 | 0.190 |
Why?
|
Glomus Tumor | 2 | 2017 | 4 | 0.190 |
Why?
|
Neoplasms, Basal Cell | 1 | 2000 | 2 | 0.180 |
Why?
|
Scalp Dermatoses | 1 | 2020 | 18 | 0.180 |
Why?
|
Immunosuppressive Agents | 2 | 2006 | 240 | 0.180 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2000 | 34 | 0.180 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 2000 | 31 | 0.180 |
Why?
|
Ki-67 Antigen | 1 | 2000 | 30 | 0.180 |
Why?
|
Lymphatic Metastasis | 2 | 2019 | 166 | 0.180 |
Why?
|
Dermis | 5 | 2009 | 16 | 0.180 |
Why?
|
Tibial Nerve | 1 | 2020 | 22 | 0.180 |
Why?
|
Alopecia | 1 | 2020 | 31 | 0.180 |
Why?
|
Predictive Value of Tests | 5 | 2013 | 873 | 0.170 |
Why?
|
Sural Nerve | 1 | 2020 | 28 | 0.170 |
Why?
|
Taxoids | 1 | 2020 | 59 | 0.170 |
Why?
|
Streptococcus | 1 | 2019 | 8 | 0.170 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2000 | 82 | 0.170 |
Why?
|
Blood Coagulation Disorders | 1 | 2019 | 13 | 0.170 |
Why?
|
Acrospiroma | 1 | 2019 | 4 | 0.170 |
Why?
|
Sweat Gland Neoplasms | 1 | 2019 | 7 | 0.170 |
Why?
|
Foot Diseases | 1 | 2019 | 10 | 0.170 |
Why?
|
Median Nerve | 1 | 2020 | 51 | 0.170 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2020 | 51 | 0.170 |
Why?
|
S100 Proteins | 4 | 2005 | 18 | 0.170 |
Why?
|
Xanthogranuloma, Juvenile | 1 | 1999 | 2 | 0.170 |
Why?
|
Eccrine Glands | 2 | 1997 | 2 | 0.170 |
Why?
|
Retrospective Studies | 7 | 2011 | 3502 | 0.160 |
Why?
|
Arteriovenous Fistula | 1 | 1999 | 18 | 0.160 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 1999 | 22 | 0.160 |
Why?
|
Actinomycosis | 1 | 1998 | 2 | 0.160 |
Why?
|
Oral Ulcer | 1 | 1998 | 5 | 0.160 |
Why?
|
Antigens, CD7 | 1 | 2018 | 4 | 0.160 |
Why?
|
Palate | 1 | 1998 | 4 | 0.160 |
Why?
|
Chondroma | 1 | 2018 | 2 | 0.160 |
Why?
|
Bone Marrow Examination | 1 | 2018 | 8 | 0.160 |
Why?
|
Vascular Neoplasms | 3 | 2009 | 12 | 0.160 |
Why?
|
Nevus | 2 | 2004 | 15 | 0.160 |
Why?
|
Vulvar Neoplasms | 2 | 2013 | 7 | 0.160 |
Why?
|
Infant | 6 | 2019 | 1059 | 0.150 |
Why?
|
Foot | 1 | 2018 | 39 | 0.150 |
Why?
|
Child, Preschool | 6 | 2013 | 1268 | 0.150 |
Why?
|
Prednisone | 3 | 2008 | 61 | 0.150 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2018 | 112 | 0.150 |
Why?
|
Lacrimal Apparatus Diseases | 1 | 2017 | 1 | 0.150 |
Why?
|
Angiomyoma | 1 | 2017 | 2 | 0.150 |
Why?
|
Eyelids | 1 | 2017 | 8 | 0.150 |
Why?
|
Lacrimal Apparatus | 1 | 2017 | 4 | 0.150 |
Why?
|
Conjunctiva | 1 | 2017 | 4 | 0.150 |
Why?
|
Conjunctival Diseases | 1 | 2017 | 4 | 0.150 |
Why?
|
Dermatitis, Allergic Contact | 1 | 2017 | 14 | 0.150 |
Why?
|
Ultrasonography | 1 | 2020 | 379 | 0.150 |
Why?
|
Administration, Oral | 2 | 2008 | 187 | 0.140 |
Why?
|
Nerve Fibers | 2 | 2020 | 37 | 0.140 |
Why?
|
Cladribine | 1 | 1996 | 1 | 0.140 |
Why?
|
Myxedema | 1 | 1996 | 3 | 0.140 |
Why?
|
Skin Pigmentation | 1 | 2017 | 26 | 0.140 |
Why?
|
Scleroderma, Systemic | 1 | 1996 | 7 | 0.140 |
Why?
|
Cell Differentiation | 3 | 2013 | 469 | 0.140 |
Why?
|
Immunoenzyme Techniques | 5 | 2004 | 52 | 0.140 |
Why?
|
Antineoplastic Agents | 2 | 2020 | 608 | 0.140 |
Why?
|
Terminology as Topic | 2 | 1993 | 64 | 0.140 |
Why?
|
Sparganosis | 1 | 2016 | 1 | 0.130 |
Why?
|
Sparganum | 1 | 2016 | 1 | 0.130 |
Why?
|
Skin Diseases, Infectious | 1 | 2016 | 2 | 0.130 |
Why?
|
Leg | 2 | 2020 | 65 | 0.130 |
Why?
|
Zoonoses | 1 | 2016 | 6 | 0.130 |
Why?
|
Hyperplasia | 4 | 2013 | 41 | 0.130 |
Why?
|
Antinematodal Agents | 1 | 2015 | 1 | 0.130 |
Why?
|
Skin Diseases, Parasitic | 1 | 2015 | 1 | 0.130 |
Why?
|
Nematoda | 1 | 2015 | 2 | 0.130 |
Why?
|
Nematode Infections | 1 | 2015 | 2 | 0.130 |
Why?
|
Telemedicine | 1 | 2017 | 102 | 0.130 |
Why?
|
Sarcoma, Kaposi | 3 | 2002 | 8 | 0.130 |
Why?
|
Emergency Service, Hospital | 1 | 2019 | 474 | 0.130 |
Why?
|
Hidradenitis | 1 | 1995 | 1 | 0.130 |
Why?
|
Liver Diseases, Alcoholic | 1 | 1995 | 6 | 0.130 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 1995 | 9 | 0.130 |
Why?
|
Herpes Simplex | 1 | 1995 | 13 | 0.130 |
Why?
|
Herpes Zoster | 1 | 1995 | 10 | 0.130 |
Why?
|
Radiography | 3 | 2019 | 376 | 0.120 |
Why?
|
Administration, Topical | 2 | 2007 | 140 | 0.120 |
Why?
|
Hemochromatosis | 1 | 1995 | 70 | 0.120 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 458 | 0.120 |
Why?
|
Liver Diseases | 1 | 1995 | 70 | 0.120 |
Why?
|
Rhinophyma | 1 | 1994 | 2 | 0.120 |
Why?
|
Mohs Surgery | 2 | 2007 | 16 | 0.120 |
Why?
|
Pruritus | 1 | 2014 | 47 | 0.120 |
Why?
|
Europe | 3 | 2016 | 82 | 0.120 |
Why?
|
Kidney Transplantation | 1 | 2019 | 517 | 0.120 |
Why?
|
Chordoma | 1 | 1994 | 7 | 0.120 |
Why?
|
Education, Medical, Continuing | 2 | 2012 | 55 | 0.120 |
Why?
|
African Americans | 1 | 2001 | 1425 | 0.120 |
Why?
|
Infrared Rays | 1 | 2013 | 18 | 0.110 |
Why?
|
Leishmaniasis, Mucocutaneous | 1 | 1993 | 1 | 0.110 |
Why?
|
Wrestling | 1 | 1993 | 2 | 0.110 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2013 | 13 | 0.110 |
Why?
|
Tinea | 1 | 1993 | 4 | 0.110 |
Why?
|
Penile Neoplasms | 2 | 2004 | 6 | 0.110 |
Why?
|
Combined Modality Therapy | 3 | 2015 | 560 | 0.110 |
Why?
|
Dysplastic Nevus Syndrome | 1 | 1993 | 2 | 0.110 |
Why?
|
Calcinosis | 1 | 2014 | 146 | 0.110 |
Why?
|
Contrast Media | 2 | 2007 | 138 | 0.110 |
Why?
|
Disease Outbreaks | 1 | 1993 | 43 | 0.110 |
Why?
|
Neoplasms, Second Primary | 1 | 1992 | 16 | 0.110 |
Why?
|
PUVA Therapy | 2 | 2009 | 22 | 0.110 |
Why?
|
Back | 2 | 2010 | 4 | 0.100 |
Why?
|
Myoepithelioma | 2 | 2003 | 2 | 0.100 |
Why?
|
Lymphoma | 1 | 1992 | 35 | 0.100 |
Why?
|
Glucocorticoids | 3 | 2009 | 147 | 0.100 |
Why?
|
Neoplasm Staging | 3 | 2010 | 447 | 0.100 |
Why?
|
Lymphocytes | 2 | 2010 | 57 | 0.100 |
Why?
|
Pain | 1 | 2014 | 288 | 0.100 |
Why?
|
Pregnancy | 1 | 2015 | 996 | 0.100 |
Why?
|
Phenotype | 1 | 2013 | 632 | 0.100 |
Why?
|
Eczema | 1 | 2011 | 13 | 0.100 |
Why?
|
Histiocytes | 2 | 2009 | 3 | 0.100 |
Why?
|
Groin | 1 | 2010 | 6 | 0.090 |
Why?
|
Inflammation | 1 | 2014 | 530 | 0.090 |
Why?
|
Lymphangioma | 2 | 2002 | 7 | 0.090 |
Why?
|
Evidence-Based Medicine | 2 | 2015 | 217 | 0.090 |
Why?
|
DNA | 1 | 1992 | 226 | 0.090 |
Why?
|
Hutchinson's Melanotic Freckle | 1 | 2010 | 2 | 0.090 |
Why?
|
Governing Board | 1 | 2009 | 1 | 0.090 |
Why?
|
Paget's Disease, Mammary | 2 | 2002 | 3 | 0.090 |
Why?
|
Genetic Predisposition to Disease | 1 | 2013 | 835 | 0.090 |
Why?
|
Fibrosis | 2 | 2007 | 120 | 0.090 |
Why?
|
History, 21st Century | 1 | 2009 | 59 | 0.090 |
Why?
|
History, 20th Century | 1 | 2009 | 71 | 0.090 |
Why?
|
Technetium Tc 99m Sulfur Colloid | 1 | 2009 | 5 | 0.090 |
Why?
|
Actins | 1 | 2009 | 51 | 0.080 |
Why?
|
Histiocytosis | 1 | 2009 | 1 | 0.080 |
Why?
|
Lymphatic Vessels | 1 | 2009 | 5 | 0.080 |
Why?
|
Clobetasol | 1 | 2009 | 26 | 0.080 |
Why?
|
Brazil | 1 | 2009 | 16 | 0.080 |
Why?
|
Mastocytosis, Cutaneous | 1 | 2008 | 3 | 0.080 |
Why?
|
Purpura | 2 | 1999 | 4 | 0.080 |
Why?
|
Radiopharmaceuticals | 1 | 2009 | 93 | 0.080 |
Why?
|
Renal Dialysis | 2 | 2003 | 279 | 0.080 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 1 | 2008 | 1 | 0.080 |
Why?
|
Granuloma Annulare | 1 | 2008 | 2 | 0.080 |
Why?
|
Lymphangiectasis | 2 | 1999 | 5 | 0.080 |
Why?
|
Survival Analysis | 2 | 2007 | 482 | 0.080 |
Why?
|
Lip | 1 | 2008 | 7 | 0.080 |
Why?
|
Melanocytes | 3 | 2001 | 8 | 0.080 |
Why?
|
Neurothekeoma | 1 | 2008 | 2 | 0.080 |
Why?
|
Histiocytosis, Langerhans-Cell | 1 | 2008 | 5 | 0.080 |
Why?
|
Endothelial Cells | 1 | 2009 | 189 | 0.080 |
Why?
|
Elastic Tissue | 1 | 2007 | 2 | 0.080 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2009 | 148 | 0.080 |
Why?
|
Factor XIIIa | 1 | 2007 | 1 | 0.080 |
Why?
|
Bone Diseases | 1 | 2008 | 18 | 0.080 |
Why?
|
Atrophy | 1 | 2007 | 46 | 0.080 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2007 | 21 | 0.080 |
Why?
|
Gadolinium | 1 | 2007 | 22 | 0.080 |
Why?
|
Methotrexate | 1 | 2008 | 64 | 0.070 |
Why?
|
Syndrome | 1 | 2007 | 72 | 0.070 |
Why?
|
Injections, Intravenous | 1 | 2007 | 78 | 0.070 |
Why?
|
Extremities | 1 | 2007 | 50 | 0.070 |
Why?
|
Fibroblasts | 1 | 2007 | 111 | 0.070 |
Why?
|
Career Choice | 1 | 2007 | 43 | 0.070 |
Why?
|
Early Diagnosis | 1 | 2007 | 62 | 0.070 |
Why?
|
Fellowships and Scholarships | 1 | 2007 | 52 | 0.070 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2007 | 78 | 0.070 |
Why?
|
Family Practice | 1 | 2007 | 51 | 0.070 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2007 | 190 | 0.070 |
Why?
|
Germany | 1 | 2006 | 6 | 0.070 |
Why?
|
Skin Ulcer | 1 | 2006 | 11 | 0.070 |
Why?
|
Polychondritis, Relapsing | 1 | 2006 | 2 | 0.070 |
Why?
|
Academic Medical Centers | 1 | 2007 | 158 | 0.070 |
Why?
|
Cytomegalovirus Infections | 1 | 2006 | 48 | 0.070 |
Why?
|
Antibodies, Monoclonal | 1 | 2008 | 246 | 0.070 |
Why?
|
Mycophenolic Acid | 1 | 2006 | 41 | 0.070 |
Why?
|
Dilatation, Pathologic | 2 | 2013 | 20 | 0.070 |
Why?
|
Cross-Sectional Studies | 2 | 2020 | 1532 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 3 | 2017 | 1328 | 0.060 |
Why?
|
Animals | 3 | 2016 | 7541 | 0.060 |
Why?
|
Microtubule-Associated Proteins | 1 | 2005 | 35 | 0.060 |
Why?
|
Nevus, Blue | 2 | 2002 | 3 | 0.060 |
Why?
|
Neuroblastoma | 1 | 2005 | 31 | 0.060 |
Why?
|
Case-Control Studies | 1 | 2007 | 893 | 0.060 |
Why?
|
Necrosis | 2 | 1995 | 53 | 0.060 |
Why?
|
Anti-Inflammatory Agents | 1 | 2006 | 99 | 0.060 |
Why?
|
Fatal Outcome | 2 | 2008 | 83 | 0.060 |
Why?
|
Recombinant Fusion Proteins | 1 | 2004 | 105 | 0.060 |
Why?
|
Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2004 | 2 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2007 | 510 | 0.060 |
Why?
|
Immunoglobulin G | 1 | 2004 | 122 | 0.060 |
Why?
|
Mixed Tumor, Malignant | 1 | 2003 | 1 | 0.060 |
Why?
|
Neurofilament Proteins | 1 | 2003 | 13 | 0.060 |
Why?
|
Genes, Retinoblastoma | 1 | 2003 | 2 | 0.060 |
Why?
|
Triamcinolone | 1 | 2003 | 11 | 0.060 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2003 | 41 | 0.060 |
Why?
|
Cell Nucleus | 2 | 1995 | 108 | 0.060 |
Why?
|
Immunoglobulins | 1 | 2003 | 15 | 0.060 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2003 | 40 | 0.060 |
Why?
|
Plasma Cells | 1 | 2003 | 11 | 0.050 |
Why?
|
Gene Deletion | 1 | 2003 | 67 | 0.050 |
Why?
|
Actinomycetales | 1 | 2002 | 2 | 0.050 |
Why?
|
Lip Neoplasms | 1 | 2002 | 2 | 0.050 |
Why?
|
Syphilis, Cutaneous | 1 | 2002 | 2 | 0.050 |
Why?
|
Skin Diseases, Papulosquamous | 1 | 2002 | 2 | 0.050 |
Why?
|
Leukemia, Lymphoid | 1 | 2002 | 3 | 0.050 |
Why?
|
Corynebacterium Infections | 1 | 2002 | 3 | 0.050 |
Why?
|
Nevus, Epithelioid and Spindle Cell | 1 | 2002 | 4 | 0.050 |
Why?
|
Angiomatosis | 1 | 2002 | 4 | 0.050 |
Why?
|
Nevus, Pigmented | 1 | 2002 | 6 | 0.050 |
Why?
|
Forearm | 2 | 2020 | 43 | 0.050 |
Why?
|
Salivary Gland Neoplasms | 1 | 2002 | 13 | 0.050 |
Why?
|
Cell Proliferation | 1 | 2005 | 604 | 0.050 |
Why?
|
Adenoma | 1 | 2002 | 35 | 0.050 |
Why?
|
Pigmentation Disorders | 1 | 2002 | 8 | 0.050 |
Why?
|
Prospective Studies | 2 | 2020 | 2278 | 0.050 |
Why?
|
Sarcoidosis | 2 | 2002 | 27 | 0.050 |
Why?
|
Neutrophils | 1 | 2002 | 106 | 0.050 |
Why?
|
Internship and Residency | 1 | 2005 | 314 | 0.050 |
Why?
|
Dermatitis, Atopic | 1 | 2002 | 102 | 0.050 |
Why?
|
Disease Progression | 2 | 2015 | 593 | 0.050 |
Why?
|
Keratins | 2 | 1998 | 39 | 0.040 |
Why?
|
Ankle | 1 | 2020 | 29 | 0.040 |
Why?
|
Albumins | 1 | 2020 | 45 | 0.040 |
Why?
|
Electrodiagnosis | 1 | 2020 | 42 | 0.040 |
Why?
|
Basal Cell Nevus Syndrome | 1 | 1999 | 2 | 0.040 |
Why?
|
Paclitaxel | 1 | 2020 | 67 | 0.040 |
Why?
|
Wrist | 1 | 2020 | 48 | 0.040 |
Why?
|
Forefoot, Human | 1 | 2019 | 3 | 0.040 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2019 | 18 | 0.040 |
Why?
|
Fibrinogen | 1 | 2019 | 44 | 0.040 |
Why?
|
Neural Conduction | 1 | 2020 | 91 | 0.040 |
Why?
|
Leukemia, Hairy Cell | 1 | 1999 | 1 | 0.040 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 1999 | 1 | 0.040 |
Why?
|
Panniculitis | 1 | 1999 | 3 | 0.040 |
Why?
|
Collagen Diseases | 1 | 1999 | 5 | 0.040 |
Why?
|
Skin Diseases, Viral | 1 | 1999 | 4 | 0.040 |
Why?
|
Psoriasis | 1 | 2004 | 360 | 0.040 |
Why?
|
Skin Diseases, Genetic | 1 | 1999 | 4 | 0.040 |
Why?
|
Vasculitis | 1 | 1999 | 24 | 0.040 |
Why?
|
Graft vs Host Disease | 1 | 1999 | 21 | 0.040 |
Why?
|
Bone Marrow Transplantation | 1 | 1999 | 63 | 0.040 |
Why?
|
Diatrizoate Meglumine | 1 | 1998 | 1 | 0.040 |
Why?
|
Hyperkeratosis, Epidermolytic | 1 | 1998 | 1 | 0.040 |
Why?
|
Drug Eruptions | 1 | 1998 | 9 | 0.040 |
Why?
|
Registries | 2 | 2010 | 298 | 0.040 |
Why?
|
Angiolipoma | 1 | 1998 | 1 | 0.040 |
Why?
|
Carcinoma, Adenosquamous | 1 | 1998 | 3 | 0.040 |
Why?
|
Angiofibroma | 1 | 1998 | 2 | 0.040 |
Why?
|
Hemangioendothelioma, Epithelioid | 1 | 1998 | 3 | 0.040 |
Why?
|
Angiomyolipoma | 1 | 1998 | 6 | 0.040 |
Why?
|
Myxoma | 1 | 1998 | 5 | 0.040 |
Why?
|
Pilot Projects | 1 | 2020 | 545 | 0.040 |
Why?
|
Software | 1 | 2018 | 123 | 0.040 |
Why?
|
Angiomatosis, Bacillary | 1 | 1997 | 1 | 0.040 |
Why?
|
Hemangioma, Cavernous | 1 | 1997 | 3 | 0.040 |
Why?
|
Angiolymphoid Hyperplasia with Eosinophilia | 1 | 1997 | 3 | 0.040 |
Why?
|
Granuloma, Pyogenic | 1 | 1997 | 4 | 0.040 |
Why?
|
Hemangioma, Capillary | 1 | 1997 | 3 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 1 | 2003 | 918 | 0.040 |
Why?
|
Hemangiopericytoma | 1 | 1997 | 6 | 0.040 |
Why?
|
Angiokeratoma | 1 | 1997 | 2 | 0.040 |
Why?
|
Venules | 1 | 1997 | 5 | 0.040 |
Why?
|
Lymphatic System | 1 | 1997 | 2 | 0.040 |
Why?
|
Neoplasm Regression, Spontaneous | 1 | 1997 | 6 | 0.040 |
Why?
|
Veins | 1 | 1997 | 29 | 0.040 |
Why?
|
Capillaries | 1 | 1997 | 24 | 0.040 |
Why?
|
Cell Lineage | 1 | 1997 | 71 | 0.040 |
Why?
|
Acute Disease | 1 | 1998 | 252 | 0.040 |
Why?
|
Aneurysm | 1 | 1997 | 21 | 0.040 |
Why?
|
Oculomotor Muscles | 1 | 1997 | 5 | 0.040 |
Why?
|
Eye Diseases | 1 | 1997 | 5 | 0.040 |
Why?
|
Observer Variation | 1 | 2017 | 105 | 0.040 |
Why?
|
Melanins | 1 | 1996 | 6 | 0.030 |
Why?
|
Sentinel Lymph Node Biopsy | 2 | 2009 | 70 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2017 | 293 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 1996 | 100 | 0.030 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 1996 | 30 | 0.030 |
Why?
|
Praziquantel | 1 | 2016 | 2 | 0.030 |
Why?
|
Seawater | 1 | 2016 | 3 | 0.030 |
Why?
|
Italy | 1 | 2016 | 15 | 0.030 |
Why?
|
Anthelmintics | 1 | 2016 | 3 | 0.030 |
Why?
|
Helminthiasis | 1 | 2015 | 1 | 0.030 |
Why?
|
Helminths | 1 | 2015 | 1 | 0.030 |
Why?
|
Tropical Climate | 1 | 2015 | 1 | 0.030 |
Why?
|
Endemic Diseases | 1 | 2015 | 4 | 0.030 |
Why?
|
Ophthalmologic Surgical Procedures | 2 | 2010 | 3 | 0.030 |
Why?
|
Glucagonoma | 1 | 1995 | 1 | 0.030 |
Why?
|
Sebaceous Glands | 1 | 1995 | 2 | 0.030 |
Why?
|
Inclusion Bodies, Viral | 1 | 1995 | 4 | 0.030 |
Why?
|
Tongue Diseases | 1 | 1995 | 4 | 0.030 |
Why?
|
Hair Follicle | 1 | 1995 | 8 | 0.030 |
Why?
|
Cytoplasm | 1 | 1995 | 29 | 0.030 |
Why?
|
Chromatin | 1 | 1995 | 25 | 0.030 |
Why?
|
Edema | 1 | 1995 | 28 | 0.030 |
Why?
|
Young Adult | 2 | 2013 | 2635 | 0.030 |
Why?
|
Serum Albumin | 1 | 1995 | 54 | 0.030 |
Why?
|
Facial Dermatoses | 1 | 1994 | 18 | 0.030 |
Why?
|
Kidney Failure, Chronic | 1 | 1999 | 541 | 0.030 |
Why?
|
Dental Instruments | 1 | 1993 | 1 | 0.030 |
Why?
|
Nails | 1 | 1993 | 6 | 0.030 |
Why?
|
Curettage | 1 | 1993 | 9 | 0.030 |
Why?
|
Onychomycosis | 1 | 1993 | 8 | 0.030 |
Why?
|
Leishmaniasis, Diffuse Cutaneous | 1 | 1993 | 1 | 0.030 |
Why?
|
Bolivia | 1 | 1993 | 2 | 0.030 |
Why?
|
Leishmaniasis, Cutaneous | 1 | 1993 | 2 | 0.030 |
Why?
|
Specimen Handling | 1 | 1993 | 33 | 0.030 |
Why?
|
Diploidy | 1 | 1993 | 2 | 0.030 |
Why?
|
Pain Measurement | 1 | 2014 | 350 | 0.030 |
Why?
|
Microscopy | 1 | 1993 | 26 | 0.030 |
Why?
|
Vascular Malformations | 1 | 2013 | 9 | 0.030 |
Why?
|
Genes, Immunoglobulin | 1 | 1992 | 4 | 0.030 |
Why?
|
Blotting, Southern | 1 | 1992 | 24 | 0.030 |
Why?
|
Gene Rearrangement | 1 | 1992 | 11 | 0.030 |
Why?
|
Antifungal Agents | 1 | 1993 | 40 | 0.030 |
Why?
|
Immunophenotyping | 1 | 1992 | 50 | 0.030 |
Why?
|
Rhabdomyosarcoma | 1 | 1992 | 6 | 0.030 |
Why?
|
Microscopy, Electron | 1 | 1992 | 30 | 0.030 |
Why?
|
Credentialing | 1 | 2012 | 9 | 0.030 |
Why?
|
Stromal Cells | 1 | 2013 | 84 | 0.030 |
Why?
|
Wilms Tumor | 1 | 1992 | 14 | 0.030 |
Why?
|
Task Performance and Analysis | 1 | 2012 | 53 | 0.030 |
Why?
|
Incidence | 1 | 2015 | 1196 | 0.030 |
Why?
|
Ploidies | 1 | 1992 | 7 | 0.030 |
Why?
|
Aneuploidy | 1 | 1992 | 10 | 0.030 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2011 | 9 | 0.020 |
Why?
|
Prevalence | 1 | 2014 | 981 | 0.020 |
Why?
|
Program Evaluation | 1 | 2012 | 185 | 0.020 |
Why?
|
Educational Measurement | 1 | 2012 | 123 | 0.020 |
Why?
|
Societies, Medical | 1 | 2012 | 163 | 0.020 |
Why?
|
Austria | 1 | 2010 | 3 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2010 | 149 | 0.020 |
Why?
|
Radiotherapy | 1 | 2010 | 82 | 0.020 |
Why?
|
Rosaniline Dyes | 1 | 2009 | 18 | 0.020 |
Why?
|
Neoplasm, Residual | 1 | 2009 | 25 | 0.020 |
Why?
|
Eyelid Diseases | 1 | 2009 | 3 | 0.020 |
Why?
|
Phosphoglucomutase | 1 | 2009 | 5 | 0.020 |
Why?
|
Intraoperative Care | 1 | 2009 | 48 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2010 | 582 | 0.020 |
Why?
|
Silver Sulfadiazine | 1 | 2008 | 4 | 0.020 |
Why?
|
Fluocinonide | 1 | 2008 | 11 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2008 | 24 | 0.020 |
Why?
|
Membrane Glycoproteins | 1 | 2009 | 101 | 0.020 |
Why?
|
Anti-Infective Agents, Local | 1 | 2008 | 15 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2009 | 297 | 0.020 |
Why?
|
Azacitidine | 1 | 2008 | 28 | 0.020 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2008 | 49 | 0.020 |
Why?
|
Time Factors | 1 | 2013 | 2147 | 0.020 |
Why?
|
Perineum | 1 | 2006 | 18 | 0.020 |
Why?
|
Cohort Studies | 1 | 2010 | 1813 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2008 | 668 | 0.020 |
Why?
|
Mitosis | 1 | 2005 | 25 | 0.020 |
Why?
|
Risk Factors | 1 | 2013 | 3867 | 0.020 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2004 | 46 | 0.020 |
Why?
|
Blotting, Western | 1 | 2005 | 289 | 0.010 |
Why?
|
Periodicals as Topic | 1 | 2005 | 91 | 0.010 |
Why?
|
Apoptosis | 1 | 2005 | 360 | 0.010 |
Why?
|
Leprosy | 1 | 2002 | 2 | 0.010 |
Why?
|
Neurofibroma | 1 | 2002 | 2 | 0.010 |
Why?
|
Leishmaniasis | 1 | 2002 | 3 | 0.010 |
Why?
|
Antibodies, Anticardiolipin | 1 | 2002 | 5 | 0.010 |
Why?
|
Germinal Center | 1 | 2002 | 5 | 0.010 |
Why?
|
Clone Cells | 1 | 2002 | 36 | 0.010 |
Why?
|
Salivary Glands, Minor | 1 | 2002 | 10 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2005 | 726 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 2004 | 220 | 0.010 |
Why?
|
HIV-1 | 1 | 2002 | 45 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2003 | 317 | 0.010 |
Why?
|
Breast | 1 | 2002 | 68 | 0.010 |
Why?
|
Neurons | 1 | 2005 | 410 | 0.010 |
Why?
|
Cholesterol | 1 | 2002 | 252 | 0.010 |
Why?
|
Pedigree | 1 | 1999 | 140 | 0.010 |
Why?
|
Breast Neoplasms, Male | 1 | 1999 | 11 | 0.010 |
Why?
|
Carbon Dioxide | 1 | 1999 | 38 | 0.010 |
Why?
|
Hysterosalpingography | 1 | 1998 | 1 | 0.010 |
Why?
|
Laser Therapy | 1 | 1999 | 55 | 0.010 |
Why?
|
Carcinoembryonic Antigen | 1 | 1998 | 7 | 0.010 |
Why?
|
Cell Adhesion Molecules | 1 | 1998 | 43 | 0.010 |
Why?
|
Depth Perception | 1 | 1997 | 1 | 0.010 |
Why?
|
Eye Movements | 1 | 1997 | 12 | 0.010 |
Why?
|
Visual Acuity | 1 | 1997 | 73 | 0.010 |
Why?
|
United States | 1 | 2005 | 3931 | 0.010 |
Why?
|
Adenocarcinoma | 1 | 1999 | 308 | 0.010 |
Why?
|
Griseofulvin | 1 | 1993 | 1 | 0.010 |
Why?
|
Ketoconazole | 1 | 1993 | 5 | 0.010 |
Why?
|
Itraconazole | 1 | 1993 | 6 | 0.010 |
Why?
|
Fluconazole | 1 | 1993 | 8 | 0.010 |
Why?
|
Molecular Structure | 1 | 1993 | 59 | 0.010 |
Why?
|